The Effect Of Vitamin D Supplementation On Clinical Symptoms And Metabolic Profiles In Patients With Endometriosis
Notes for this study:
||Average hs-CRP decreased from 3.7 ± 0.9 to 3.0 ± 0.8 mg/L in treatment group (p <.001)
|Number of Subjects
60 women aged 18-40 with endometriosis were randomized to take either a megadose of vitamin D (50,000 IU) or placebo every 2 weeks for 12 weeks. 1/6 of the patients withdrew from the study, leaving 25 women in each group.
Funding issues for this study:
The treatment (Vitamin D) group had a greater decrease in dysmenorrhea than the placebo group, although the treatment group had higher pain scores to begin with. (There's no mention of the pain scale in the study.) There was no significant difference with regard to pain during sex or defecation.
The study measured 15 blood parameters and found a significant difference between placebo and treatment for the following: hs-CRP slightly increased for the placebo group and decreased for the treatment group; total antioxidant capacity (TAC) increased dramatically for the vitamin D treatment group; and total-/HDL-cholesterol ratio decreased more for treatment than for placebo. The study didn't correct statistically for multiple outcomes.
The current study was funded by a grant from the Vice-chancellor for Research, IUMS, and Iran.